分化型早期胃癌治愈性内镜切除后的第二胃癌:单臂确证性试验的事后分析
本事后分析基于单臂确证性试验JCOG0607数据集,纳入317例接受治愈性内镜切除的分化型早期胃癌患者,中位随访6.0年。1年遗漏胃癌累积发生率为7.6%,5年异时性胃癌累积发生率为12.7%,多数病灶可经内镜切除治疗。
要点
- 治愈性内镜切除后1年遗漏胃癌累积发生率为7.6%,5年异时性胃癌累积发生率为12.7%。
- 中位随访6.0年期间共检出30处遗漏胃癌和61处异时性胃癌,分别见于24例和48例患者。
- 多数第二胃癌病灶仍满足治愈性内镜切除的病理标准,可行内镜切除治疗。
核心结论
- 本研究首次揭示了分化型早期胃癌治愈性内镜切除后第二胃癌的实际发生率,多数病灶可经内镜切除治疗,治愈性内镜切除后持续内镜监测对检出第二胃癌很重要。
研究设计与样本
- 本研究为单臂确证性试验JCOG0607的事后分析,纳入317例接受治愈性内镜切除的患者。
- JCOG0607关键纳入标准为单发分化型早期胃癌且既往无胃切除或早期胃癌内镜治疗史。
- 监测内镜在初始内镜切除后1至3个月进行,此后每年一次至少持续5年。
主要发现
- 中位随访6.0年(四分位距5.1至7.0年)期间,24例患者检出30处遗漏胃癌,48例患者检出61处异时性胃癌。
- 1年遗漏胃癌累积发生率为7.6%,5年异时性胃癌累积发生率为12.7%。
- 85处病灶接受内镜切除,6处病灶接受胃切除术。
- 病理评估显示78处黏膜癌、12处黏膜下癌和1处进展期癌。
- 最终28处遗漏胃癌和52处异时性胃癌满足治愈性内镜切除的病理标准。
关键数值与推荐
- 遗漏胃癌定义为初始内镜切除后1年及以内检出的病灶,异时性胃癌定义为初始内镜切除后超过1年检出的病灶。
临床怎么用
- 原文结论指出治愈性内镜切除后持续内镜监测对检出第二胃癌很重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic resection (ER) for early gastric cancer (EGC) can preserve the stomach; however, the remaining stomach can develop second gastric cancer. Few reports have prospectively investigated the incidence and treatment outcomes of second gastric cancer. METHODS: This post-hoc analysis used the dataset of the single-arm confirmatory trial, JCOG0607. The key inclusion criteria for JCOG0607 were solitary differentiated-type EGC and no previous gastrectomy or endoscopic treatment for EGC. Three hundred seventeen patients who underwent curative ER were included in this study. Surveillance endoscopy was performed 1 to 3 months after the initial ER and subsequently annually for at least 5 years. A lesion detected ≤1 year and >1 year after the initial ER was defined as overlooked gastric cancer (OGC) and metachronous gastric cancer (MGC), respectively. RESULTS: During a median follow-up period of 6.0 years (interquartile range, 5.1-7.0), 30 OGCs and 61 MGCs were detected in 24 and 48 patients, respectively. The cumulative incidence of OGC at 1 year and MGC at 5 years was 7.6% and 12.7%, respectively. ER and gastrectomy were performed in 85 lesions and 6 lesions, respectively. Pathologic evaluation showed 78 mucosal cancers, 12 submucosal cancers, and 1 advanced cancer. Eventually, 28 OGCs and 52 MGCs fulfilled the pathologic criteria for curative ER. CONCLUSIONS: Our study was the first to reveal the actual incidence of second gastric cancer after curative ER for differentiated-type gastric cancer. Most lesions could be treated with ER. Continuous endoscopic surveillance after curative ER is important to detect second gastric cancer.
引用
- Yoshida M, Takizawa K, Hasuike N, et al. Second gastric cancer after curative endoscopic resection of differentiated-type early gastric cancer: post-hoc analysis of a single-arm confirmatory trial. Gastrointest Endosc. 2021. PMID: 34919940. doi:10.1016/j.gie.2021.11.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。